Holen Sie sich die Stockscreener-App
3.26
8.94%
-0.32
Handel nachbörslich:
3.28
0.02
+0.61%
Anixa Biosciences Inc Aktie (ANIX) Neueste Nachrichten
ANIX: Breast cancer vaccine phase I showed 75% robust immune response and strong safety profile - TradingView — Track All Markets
Cleveland Clinic transfers breast cancer vaccine IND to Anixa - marketscreener.com
Anixa Biosciences (ANIX) Advances Breast Cancer Vaccine Developm - GuruFocus
Anixa Biosciences takes over breast cancer vaccine IND from Cleveland Clinic - Investing.com
Anixa Biosciences takes over breast cancer vaccine IND from Cleveland Clinic By Investing.com - Investing.com South Africa
Anixa Biosciences (NASDAQ: ANIX) assumes IND, plans Phase 2 cancer vaccine trial - Stock Titan
D. Boral Capital Maintains Anixa Biosciences (ANIX) Buy Recommendation - Nasdaq
Anixa Biosciences (ANIX) Shares Drop 21% After Phase 1 Vaccine D - GuruFocus
Anixa Biosciences falls on phase 1 data for breast cancer vaccine - Seeking Alpha
Anixa Biosciences (NASDAQ:ANIX) Given "Buy" Rating at D. Boral Capital - MarketBeat
ANIX: D. Boral Capital Maintains Buy Rating with $10 Price Targe - GuruFocus
Anixa Biosciences Reports Positive Phase 1 Trial Results - TipRanks
Anixa Biosciences Inc Announces Positive Phase 1 Data for Breast Cancer Vaccine - TradingView — Track All Markets
Anixa Biosciences Says Breast Cancer Vaccine Candidate Meets Key Endpoints in Phase 1 Trial - marketscreener.com
Anixa Biosciences Shares Jump Over 15% In After-Hours Trading — Here's Why - Benzinga
Anixa Biosciences (ANIX) Presents Promising Phase 1 Breast Cance - GuruFocus
Anixa’s breast cancer vaccine shows positive Phase 1 results - Investing.com
Anixa Biosciences (NASDAQ: ANIX) Phase 1 breast cancer vaccine data met endpoints with 74% immune response - Stock Titan
Cleveland Clinic Presents Final Results of Phase 1 Clinical Trial of Preventive Breast Cancer Vaccine Study - Cleveland Clinic Newsroom
Anixa Biosciences Inc (NASDAQ:ANIX) Given Average Rating of "Hold" by Brokerages - MarketBeat
Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025 - sharewise.com
Anixa Biosciences (NASDAQ: ANIX) sets Dec. 15 talk on Phase 1 breast cancer vaccine - Stock Titan
Anixa Biosciences (NASDAQ: ANIX) unveils final Phase 1 breast cancer vaccine results at 2025 SABCS - Stock Titan
Will Anixa Biosciences Inc. (CY71) stock beat Nasdaq index returns2025 Risk Factors & Real-Time Stock Entry Alerts - Newser
Why Anixa Biosciences Inc. (CY71) stock is trending on social mediaPortfolio Update Report & Fast Momentum Stock Entry Tips - Newser
Will Anixa Biosciences Inc. stock see PE expansionWeekly Trading Summary & Risk Controlled Stock Pick Alerts - Newser
Is Anixa Biosciences Inc. stock undervalued vs historical averagesJuly 2025 WrapUp & Free Technical Pattern Based Buy Signals - Newser
Who are in the management team of Anixa Biosciences, Inc.? - Markets Mojo
Is Anixa Biosciences Inc. stock a bargain at current levelsJuly 2025 Opening Moves & Community Consensus Stock Picks - Newser
How risky is Anixa Biosciences Inc. (CY71) stock compared to peersLayoff News & Accurate Intraday Trading Signals - Newser
Can Anixa Biosciences Inc. (CY71) stock sustain double digit ROEJuly 2025 Action & Stepwise Trade Signal Implementation - Newser
How Anixa Biosciences Inc. stock compares to growth peersJuly 2025 Catalysts & Risk Adjusted Buy/Sell Alerts - Newser
Anixa Biosciences (ANIX) Stock Analysis Report | Financials & Insights - Benzinga
Why retail investors pile into Anixa Biosciences Inc. stock2025 Institutional Moves & High Accuracy Trade Alerts - moha.gov.vn
Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial (PR Newswire) - Aktiellt
Can Anixa Biosciences Inc. stock attract ESG capital inflows2025 Top Decliners & Low Risk High Win Rate Stock Picks - moha.gov.vn
Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization - Quantisnow
Anixa Biosciences (NASDAQ:ANIX) Stock Rating Lowered by Zacks Research - MarketBeat
Is Anixa Biosciences Inc. stock a top momentum playGold Moves & Precise Entry and Exit Recommendations - newser.com
How geopolitical risks impact Anixa Biosciences Inc. (CY71) stockWeekly Trade Recap & High Return Trade Guides - newser.com
Why Anixa Biosciences Inc. stock is recommended by analysts2025 Risk Factors & Long-Term Growth Portfolio Plans - newser.com
Anixa Biosciences (ANIX) Price Target Increased by 11.11% to 10.20 - MSN
Intraday pattern recognizer results for Anixa Biosciences Inc.July 2025 EndofMonth & Reliable Price Breakout Alerts - newser.com
Anixa Biosciences Inc. stock prediction for this week2025 Bull vs Bear & Daily Volume Surge Signals - newser.com
Can Anixa Biosciences Inc. (CY71) stock resist broad market declinesPortfolio Value Summary & Real-Time Stock Entry Alerts - newser.com
Will Anixa Biosciences Inc. stock benefit from commodity pricesWeekly Trend Recap & Consistent Profit Alerts - newser.com
0.36%
1.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):